Key oncology conferences like ASCO, ASH, and ESMO drive investment-informing clinical research, with recent ESMO 2024 data highlighting significant advancements in immunotherapy. Merck's ...

Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – showed that nearly two-thirds (61.6%) of patients with brain metastases ...

Jazz’s Global Head of R&D Robert Iannone, M.D., told Fierce Biotech ahead of ESMO that today’s updated results “reaffirm zanidatamab’s potential as a foundational treatment for patients ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market. It worked by rousing the body’s own immune cells to attack tumors. Within months, regulators had approved ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

NCI investigator John Haanen told the ESMO congress that TIL therapy improved PFS compared to Yervoy by 50%, 7.2 months versus 3.1 months with Yervoy, which was a significant improvement.

Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...

Press conference: 12:30-13:15 CEST - ESMO Press Conference room, CC3 and virtually Presidential Symposium III, Eyes to the future: 16:30-18:15 CEST - Barcelona Auditorium - Hall 2 Organ agnostic ...

More than 30,000 people will descend on Barcelona, Spain, this week for the 2024 European Society for Medical Oncology (ESMO) Congress, which runs from September 13 to 17. Since the meeting's ...